PDS BIOTECHNOLOGY CORPORATION - COMMON STOCK

PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer

15 Dec 2022 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Executives to Present an Overview of Oncology and Infectious Disease Programs at the World Vaccine & Immunotherapy Congress

21 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update

14 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial

14 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Presentation of Preliminary PDS0101 Efficacy, Safety, and Immunology Data at Society for Immunotherapy of Cancer (SITC 2022)

07 Nov 2022 08:00:03 By Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2022 Financial Results

31 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable

27 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Chief Medical Officer Dr. Lauren V. Wood to Address 2022 International Head and Neck Conference

25 Oct 2022 08:00:02 By Nasdaq GlobeNewswire

PDS Biotech to Present at the LD Micro Main Event XV

19 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Abstract Demonstrating Versatility of the Versamune® Platform in Oncology Accepted for Presentation at AACR Special Conference on Tumor Immunology and Immunotherapy

17 Oct 2022 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech to Host Head and Neck Cancer KOL Roundtable on October 26, 2022

12 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers

11 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Reports An Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

07 Oct 2022 16:01:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Abstracts Involving Research of PDS0101 Accepted for Presentation at SITC 2022

05 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Successful End-of-Phase 2 Meeting With the FDA and Preparation for the Registrational Trial of PDS0101 in Combination With KEYTRUDA®

03 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

23 Sep 2022 16:05:00 By Nasdaq GlobeNewswire

PDS Biotech to Participate at Cantor Fitzgerald’s Oncology & HemOnc Conference

22 Sep 2022 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers

21 Sep 2022 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech to Participate at H.C. Wainwright 24th Annual Global Investment Conference

06 Sep 2022 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance

24 Aug 2022 16:01:00 By Nasdaq GlobeNewswire